The most frequently reported anti-PD-1/PD-L1 antibody–related adverse events were fatigue (15%; 95% CI, 13–16%; Supplementary Figure 7), decreased appetite (11%; 95% CI, 9–13%; Supplementary Figure 7), and nausea (10%; 95% CI, 9–11%; Supplementary Figure 7); docetaxel-treated patients most frequently had fatigue (30%; 95% CI, 25–34%; Supplementary Figure 8), alopecia (29%; 95% CI, 23–36%; Supplementary Figure 8), neutropenia (22%; 95% CI, 12–32%; Supplementary Figure 8), nausea (22%; 95% CI, 16–29%; Supplementary Figure 8), and diarrhea (20%; 95% CI, 18–23%; Supplementary Figure 8). The gene discussed is PDCD1; the disease is neutropenia.